GLP-1 agonists

The aim of study was to investigate the efficacy, safety, and tolerability of oral Semaglutide ( Rybelsus ) added to...


Among patients recently hospitalized with heart failure and reduced left ventricular ejection fraction ( LVEF ), the use of the...


A systematic review and meta-analysis has investigated the risk of pancreatitis associated with the use of incretin-based treatments in patients...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda (...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an...


The Committee for Medicinal Products for Human Use ( CHMP ) has finalised a review of GLP-1-based diabetes therapies. The...


The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations...


Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta...